Glibenclamide

Glibenclamide (Glyburide)

Glibenclamide, also known as glyburide, is an oral medication used in the management of type 2 diabetes mellitus. It is typically recommended to be used in conjunction with a proper diet and exercise regimen and may be combined with other antidiabetic medications.

Molecular structure of Glibenclamide (Glyburide)

Overview

Glibenclamide works by increasing the release of insulin from the pancreas, thereby lowering blood sugar levels. It belongs to a class of medications known as sulfonylureas.

Usage and Administration

• Indications: Primarily prescribed for the control of blood sugar in type 2 diabetes.
• Administration: It is taken orally, with dosage depending on the individual patient's response and medical condition.

History

Glibenclamide was first discovered in 1969 and was approved for medical use in the United States in 1984. It is now widely available as a generic medication.

Comparative Efficacy

While effective for many individuals, glibenclamide may not be suitable for everyone. It is not recommended as a monotherapy in type 1 diabetes and has different efficacy profiles compared to newer antidiabetic medications.

Precautions and Side Effects

Potential side effects include hypoglycemia (low blood sugar levels), weight gain, and gastrointestinal disturbances. Patients are advised to monitor their blood sugar regularly and be aware of the signs of hypoglycemia.

Prescription Trends

In 2017, glibenclamide was the 174th most commonly prescribed medication in the United States, with over three million prescriptions.

See Also

• Diabetes Mellitus
• Antidiabetic Drug
• Sulfonylurea

External Links

• National Center for Biotechnology Information - Glibenclamide
• American Diabetes Association - Oral Medication Options

References

<references>

• Johnson, M. L., & Smith, R. H. (2023). Glibenclamide in Type 2 Diabetes Management: A Review. Journal of Endocrinology and Metabolism, 45(2), 158-165.
• Patel, K. M., & Davis, P. J. (2022). Comparative Efficacy of Antidiabetic Agents: Where Does Glibenclamide Stand? American Journal of Therapeutics, 29(4), e345-e352.

</references>

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia